Iris Pharma and Clirophtha Merger Creates Unique Ophthalmology CRO

Published: Jan 04, 2008

Nice (France), 17 December 2007 – Iris Pharma of France, a specialist contract research organisation (CRO) for pre-clinical research in ophthalmology, has announced the completion of its merger with Clirophtha, a unique CRO in Europe and North America that is completely dedicated to ophthalmology clinical trials. The new entity will be known as Iris Pharma.

“The merger of Iris Pharma and Clirophtha is an opportunity to increase pharmaceutical and biotech companies’ ability to develop the potential of their ophthalmologic drugs,” says Dr Pierre-Paul Elena, Founder and CEO of Iris Pharma.

Back to news